Baxter Q3 sales rise 5% to $2.98 billion; company raises 2026 outlook
Baxter reported third-quarter 2026 sales of $2.98 billion, up 5% on both a reported and organic basis, and GAAP diluted EPS of $0.57 versus a loss of $0.09 a year earlier. Adjusted diluted EPS fell 16% to $0.58, and the company raised its full-year 2026 outlook, including adjusted EPS of $2.05 to $2.15. The board also declared a $0.01 quarterly dividend payable January 4, 2027.
Key points
- Q3 sales of approximately $2.98 billion, up 5% reported and organic; U.S. sales up 3% reported, international up 7% reported
- GAAP diluted EPS of $0.57 versus a loss of $0.09 a year earlier; adjusted diluted EPS of $0.58, down 16% from $0.69, due to a higher effective tax rate
- Full-year 2026 adjusted EPS outlook raised to $2.05 to $2.15 from $1.95 to $2.15; reported sales growth raised to 4% to 5% from 3% to 4%
- Quarterly dividend of $0.01 per share, record date November 27, 2026, payable January 4, 2027
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 7, 2026, 11:17 PM ET, from the text of the filing and its press-release exhibits only.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.